@article{0fdb864313bd492898a0942cde213479,
title = "A New Generation of Vaccines in the Age of Immunotherapy",
abstract = "Purpose of review: Cancer vaccines are one of the most extensively studied immunotherapy type in solid tumors. Despite favorable presuppositions, so far, the use of cancer vaccines has been associated with disappointing results. However, a new generation of vaccines has been developed, promising to revolutionize the immunotherapy field. Recent findings: In this review, we aim to highlight the advances in cancer vaccines and the remaining hurdles to overcome. Summary: Cancer vaccination has experienced tremendous progress in the last decade, with myriad promising developments. Future efforts should focus on optimization of target identification, streamlining of most appropriate vaccination strategies, and adjuvant development, as well as predictive biomarker identification. Cautious optimism is warranted in the face of early successes seen in recent clinical trials for oncolytic vaccines. If an approach were to prove successful, it could revolutionize cancer therapy the way ICIs did in the previous decade.",
keywords = "Immunotherapy, Lung cancer, NSCLC, Vaccines",
author = "Alfredo Addeo and Alex Friedlaender and Elisa Giovannetti and Alessandro Russo and {de Miguel-Perez}, Diego and Oscar Arrieta and Cardona, {Andres F.} and Christian Rolfo",
note = "Funding Information: Dr. Friedlander reports personal fees from Bristol-Myers Squibb, Roche, Pfizer, Merck Sharp and Dohme, and Astellas outside the submitted work; Dr. Addeo reports personal fees from Bristol-Myers Squibb, AstraZeneca, Roche, Pfizer, Merck Sharp and Dohme, and Boehringer-Ingelheim; Dr. Russo reports personal fees for attending advisory board meetings from Astra Zeneca, MSD, and Novartis outside the submitted work. Dr. Arrieta reports personal fees from Pfizer, grants and personal fees from AstraZeneca, grants, personal fees from Boehringer-Ingelheim, personal fees from Lilly, personal fees from Merck, personal fees from Bristol-Myers Squibb, and grants and personal fees from Roche, outside the submitted work; Dr. Cardona discloses financial research support from Merck Sharp & Dohme, Boehringer-Ingelheim, Roche, Bristol-Myers Squibb, Foundation Medicine, Roche Diagnostics, Thermo Fisher, Broad Institute, BioNTech, Amgen, Flatiron Health, Teva Pharma, Rochem Biocare, Bayer, INQBox, and The Foundation for Clinical and Applied Cancer Research – FICMAC. Additionally, he was linked and received honoraria as advisor, participated in speakers{\textquoteright} bureau, and gave expert testimony to EISAI, Merck Serono, Janssen Pharmaceutical, Merck Sharp & Dohme, Boehringer-Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant Health, Illumina, and Foundation for Clinical and Applied Cancer Research – FICMAC; Dr. Rolfo reports grants for Lung Cancer Research Foundation-Pfizer Grant 2019 NHI U54 grant (Project co-leader). He has received personal fees for attending advisory board with Inivata, ArcherDx, MD Serono, BMS, Novartis, and Boston Pharmaceuticals; fee for speaking bureau: MSD, Astra Zeneca, Roche. Non-financial conflict included research collaboration: Guardant Health. The other authors have non-financial relationship to disclose. Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2021",
month = dec,
day = "1",
doi = "https://doi.org/10.1007/s11912-021-01130-x",
language = "English",
volume = "23",
journal = "Current oncology reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "12",
}